{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T06:25:15Z","timestamp":1725776715238},"reference-count":38,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":525,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2000,7,17]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>1. Leukaemia inhibitory factor (LIF) is a 180 amino acid single\u2010chain protein, named after its effect on haematopoietic cells. Leukaemia inhibitory factor belongs to a group of cytokines that includes ciliary neurotrophic factor, interleukin (IL)\u20106, IL\u201011, cardiotrophin\u20101 and oncostatin M. All group members use the gp130 signal transducing subunit for intracellular signalling, but show differences in biological effect.<\/jats:p><jats:p>2. Research over the past 6\u20138 years has shown LIF to have potent neuromuscular activity. <jats:italic>In vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> studies on axotomy and nerve crush models demonstrate a powerful effect of LIF in enhancing the survival of both motor and sensory neurons, while reducing denervation\u2010induced muscle atrophy. In models of both axotomy induced neuronal death and in the <jats:italic>wobbler<\/jats:italic> mouse, LIF is active at doses as low as 1 \u03bcg\/kg delivered systemically.<\/jats:p><jats:p>3. In muscle, LIF will increase the rate of muscle regeneration <jats:italic>in vivo<\/jats:italic> when applied exogenously after injury and will stimulate intrinsic muscle repair following its targeted release to dystrophic muscle in the <jats:italic>mdx<\/jats:italic> mouse. Leukaemia inhibitory factor may also have a role as an adjunct to myoblast transfer therapy, with studies showing that the transplantation of genetically competent myoblasts into <jats:italic>mdx<\/jats:italic> mouse muscle is enhanced when cells are injected with LIF.<\/jats:p><jats:p>4. Distribution and pharmacokinetic studies have been conducted in primates with doses of 20 \u03bcg\/kg recombinant human LIF given subcutaneously over 2 weeks tolerated without major side effects.<\/jats:p><jats:p>5. A pharmaceutical form of recombinant human LIF (AM424; AMRAD Operations, Richmond, Victoria, Australia) entered human clinical trials during 1997 and a phase I clinical trial in healthy volunteers has been completed. A phase I repeat dose study has also been completed in cancer patients undergoing chemotherapy. The primary indication for a phase II study is the treatment of chemotherapy induced peripheral neuropathy. Other potential indications include muscle wasting diseases, acute nerve trauma and motor neuron disease.<\/jats:p><jats:p>6. The role of LIF in modulating nerve loss should make it an ideal candidate for the treatment of a number of neurological conditions. The phase I study represents the first trial in a programme for the clinical development of AM424.<\/jats:p>","DOI":"10.1046\/j.1440-1681.2000.03289.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T11:07:24Z","timestamp":1047380844000},"page":"553-557","source":"Crossref","is-referenced-by-count":13,"title":["AM424: History Of A Novel Drug Candidate"],"prefix":"10.1111","volume":"27","author":[{"given":"John","family":"Kurek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_12_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0968-0004(92)90505-4"},{"key":"e_1_2_12_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1992.tb16601.x"},{"key":"e_1_2_12_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1542794"},{"key":"e_1_2_12_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/stem.5530120303"},{"key":"e_1_2_12_6_2","first-page":"245","article-title":"Reconstitution of high affinity leukaemia inhibitory factor (LIF) receptors in haemopoietic cells transfected with the cloned human LIF receptor.","volume":"167","author":"Gearing DP","year":"1992","journal-title":"Ciba Found. Symp."},{"key":"e_1_2_12_7_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.3.1119"},{"key":"e_1_2_12_8_2","first-page":"227","article-title":"Distribution and binding properties of receptors for leukaemia inhibitory factor.","volume":"167","author":"Hilton DJ","year":"1992","journal-title":"Ciba Found. Symp."},{"key":"e_1_2_12_9_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8390097"},{"key":"e_1_2_12_10_2","unstructured":"WaringPM.Leukemia inhibitory factor. In: Garland J Quesenberry P Hilton D (eds).Colony Stimulating Factors: Molecular and Cellular Biology.Marcel Dekker Inc. New York. 1997; Ch. 21."},{"key":"e_1_2_12_11_2","doi-asserted-by":"crossref","first-page":"11 648","DOI":"10.1016\/S0021-9258(19)78174-5","article-title":"Ciliary neurotrophic factor\/leukemia inhibitory factor\/interleukin 6\/oncostatin M family of cytokines induces tyrosine phosphorylation of a common set of proteins overlapping those induced by other cytokines and growth factors.","volume":"269","author":"Boulton TG","year":"1994","journal-title":"J. Biol. Chem."},{"key":"e_1_2_12_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.1041640112"},{"key":"e_1_2_12_13_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8272873"},{"key":"e_1_2_12_14_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.12-09-03427.1992"},{"key":"e_1_2_12_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6273(94)90163-5"},{"key":"e_1_2_12_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.1997.tb01479.x"},{"key":"e_1_2_12_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(199901)22:1<78::AID-MUS12>3.0.CO;2-I"},{"key":"e_1_2_12_18_2","first-page":"75","article-title":"Changes in neuropeptide phenotype after axotomy of adult peripheral neurons and the role of leukemia inhibitory factor.","volume":"4","author":"Zigmond RE","year":"1996","journal-title":"Perspect. Dev. Neurobiol."},{"key":"e_1_2_12_19_2","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1523\/JNEUROSCI.15-03-02081.1995","article-title":"Differential influence of nerve growth factor on neuropeptide expression in vivo: A novel role in peptide suppression in adult sensory neurons.","volume":"15","author":"Verge VM","year":"1995","journal-title":"J. Neurosci."},{"key":"e_1_2_12_20_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.13.7727"},{"key":"e_1_2_12_21_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.15.7109"},{"key":"e_1_2_12_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/neu.480250407"},{"key":"e_1_2_12_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1996.67041751.x"},{"key":"e_1_2_12_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.1996.tb00744.x"},{"key":"e_1_2_12_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1997.tb46157.x"},{"key":"e_1_2_12_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199404000-00034"},{"key":"e_1_2_12_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.490370207"},{"key":"e_1_2_12_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(95)00263-2"},{"key":"e_1_2_12_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4547(19961001)46:1<122::AID-JNR15>3.0.CO;2-7"},{"key":"e_1_2_12_30_2","unstructured":"DonatoR CheemaSS FinkelsteinD BartlettPF MorrisonW.Role of leukaemia inhibitory factor (LIF) in rat peripheral nerve regeneration.Ann. Acad. Med. Singapore1995;24(Suppl. 4): 94\u2013100."},{"key":"e_1_2_12_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4547(19970115)47:2<208::AID-JNR9>3.0.CO;2-J"},{"key":"e_1_2_12_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880181122"},{"key":"e_1_2_12_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(91)90045-9"},{"key":"e_1_2_12_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(92)90149-F"},{"key":"e_1_2_12_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-0186(95)00014-Y"},{"key":"e_1_2_12_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(199707)20:7<815::AID-MUS5>3.0.CO;2-A"},{"key":"e_1_2_12_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(94)90211-9"},{"key":"e_1_2_12_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(96)12802-0"},{"key":"e_1_2_12_39_2","first-page":"177","article-title":"The role of growth factors in myoblast transfer therapy.","volume":"7","author":"Bower J","year":"1997","journal-title":"Basic Appl. Myol."}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1440-1681.2000.03289.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1440-1681.2000.03289.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T09:53:48Z","timestamp":1698573228000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1440-1681.2000.03289.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,7,17]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2000,7,17]]}},"alternative-id":["10.1046\/j.1440-1681.2000.03289.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1440-1681.2000.03289.x","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"value":"0305-1870","type":"print"},{"value":"1440-1681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,7,17]]}}}